BURLINGTON, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that because Phase III trials of Pfizer's tanezumab for the treatment of osteoarthritis pain were halted over U.S. Food & Drug Administration safety concerns, Decision Resources' Pharmaview 2016 global sales forecast for tanezumab has been reduced by $1.2 billion to $200 million. The decision to end the trial was made after a subset of patients in the trial required joint replacement surgery due to worsened conditions.
The discontinuation of the trial is a setback for the drug and a concern for the entire drug class, as tanezumab was the most clinically advanced agent of a family of anti-nerve growth factor (NGF) monoclonal antibodies (MAbs). Anti-NGF MAbs have garnered considerable attention from large pharmaceutical companies for the novel mechanism of action; Sanofi-Aventis (SAR164877), Johnson & Johnson (AMG-403) and Abbott (PG-110) are each in an early-stage program.
"With Lipitor, Celebrex and Viagra all facing patent expiries over the next several years, Pfizer greatly needs new agents to fill the revenue gap," said Pharmaview Analyst Michael Latwis, M.B.A. "Unfortunately, given that approval for osteoarthritis pain—the largest potential market for tanezumab—is highly unlikely, our Pharmaview model does not expect sales to reach anywhere near blockbuster status."
New Pharmaview Platform ReleasedDecision Resources has released a new delivery platform for its Pharmaview product. Pharmaview provides continually updated analysis on more than 2,100 drugs from more than 250 companies, covering 150 product classes and 14 therapy areas—complete with more than 1,200 product-level forecasts.
The new platform includes not only expanded coverage of the biopharmaceutical industry, but enhanced functionality including improved search capabilities and prominent graphical data. An easy-to-navigate interface that includes hyperlinked content points users to related industry, company and therapeutic-area analysis. Pharmaview subscribers have access to competitive assessment calls on current industry issues and Market Analyzer, a quantitative tool that allows users to track market sizes, assess barriers to market entry, quickly benchmark internal forecasts and analyze the potential of a licensing candidate.
Members of the media may contact Lisa Osgood at firstname.lastname@example.org with data requests from the new Pharmaview platform.
About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood
|SOURCE Decision Resources|
Copyright©2010 PR Newswire.
All rights reserved